{"id":"W4239172580","doi":"10.1182/blood.v120.21.798.798","title":"Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; ABVD; Medicine; Dacarbazine; Vinblastine; Internal medicine; Oncology; Regimen; Bleomycin; Hodgkin's lymphoma; Lymphoma; Chemotherapy; Vincristine; CD30","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006379231,0.0004076217,0.001186918,0.0003057401,0.000252254,0.0005391918,0.0003223698,0.0003657157,0.001373747],"category_scores_gemma":[0.0005179484,0.0002521264,0.0004503166,0.0002510039,0.0002793861,0.0004460283,0.0002474208,0.001090421,0.0002689558],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005186371,"about_ca_system_score_gemma":0.0004400113,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005262423,"about_ca_topic_score_gemma":0.001674432,"domain_scores_codex":[0.9997569,0.00009049715,0.00001451289,0.00004970581,0.00003764601,0.00005077035],"domain_scores_gemma":[0.9996233,0.00007228561,0.00006136479,0.00002460811,0.0000200542,0.0001984181],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4626327,0.04074929,0.08365027,0.0009257821,0.001441909,0.0008845386,0.0006305854,0.003941908,0.06707487,0.0002955583,0.004802519,0.33297],"study_design_scores_gemma":[0.1027276,0.7230309,0.1522404,0.0001513585,0.0008716423,0.0008337846,0.0001765566,0.004297991,0.007031272,0.0002502936,0.00834022,0.00004786276],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966335,0.001830446,0.0001472187,0.00008200842,0.00005415723,0.0002458412,0.0002016371,0.0000226032,0.0007825567],"genre_scores_gemma":[0.9978015,0.000731035,0.0002962747,0.0001462515,0.00006734549,0.0001654021,0.0003417112,0.000003804597,0.0004466974],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001373747,"threshold_uncertainty_score":0.004595637,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009071070798672023,"score_gpt":0.227760569386442,"score_spread":0.21868949858777,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}